Metrics as of 10/13/2026, 06:53 PM (Berlin time), refresh in progress.
Neurogene Stock
Neurogene Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Rachel L. McMinn
- Employees
- 131
- Market cap
- $341 M
- IPO
- 07/03/2014
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and…
Neurogene stock: price history
1D
-11.8%
1W
-15.3%
1M
-39.2%
6M
+3.9%
YTD
+4.7%
1Y
-31.8%
2Y
-56.4%
5Y
-83.8%
10Y
-89.9%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~10% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 12/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Neurogene
Analyst assessment of Neurogene
PRICE TARGET LOW
US$65.00
CONSENSUS
US$72.00
MEDIAN
US$70.00
PRICE TARGET HIGH
US$81.00
0
STRONG BUY
6
BUY
1
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 12/08/2026
Neurogene stock metrics
P/E
-3.91
P/B
2.24
EV/EBITDA
-2.19
RETURN ON EQUITY
-15.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
79.3%
FLOAT SHARES
12,536,664
AVG. DAILY VOLUME (30D)
317,140
Insider transactions (SEC)
McMinn Rachel
Cvijic Christine Mikail
Cvijic Christine Mikail
Cvijic Christine Mikail
Cvijic Christine Mikail
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Neurogene stock
What does Neurogene do?
Neurogene Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Rachel L. McMinn, the company employs around 131 people.
The IPO was on 07/03/2014; the stock trades on NASDAQ under the ticker NGNE.
What do analysts say about Neurogene stock?
7 analysts rate the stock, the consensus is Buy (as of 12/08/2026).
The average price target is US$72.00, ranging from US$65.00 to US$81.00, with a median of US$70.00.
This is an external assessment, not a statement by Market Jury.
When does Neurogene report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 10% stronger than usual.
Does Neurogene pay a dividend?
No, Neurogene currently does not pay a dividend.
Which stocks are comparable to Neurogene?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Neurogene stock analyzed?
Clicking "Analyze stock" lets five strategies assess Neurogene against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.